Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Tudriqev Coverage Policy | OpenPayer
    Ask Trek AI about this page
    ModifiedQualChoicePolicy CP.PHAR.774

    Vusolimogene Oderparepvec-wtpg (Tudriqev) Coverage Criteria

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PHAR.774 alerts

    Get alerted when Policy CP.PHAR.774 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Tudriqev, including initial and continuation therapy, for QualChoice commercial, HIM/ICHRA, and Medicaid members.

    Policy Summary
    PayerQualChoice
    PolicyVusolimogene Oderparepvec-wtpg (Tudriqev) Coverage Criteria
    Policy CodePolicy CP.PHAR.774
    Change TypeModified
    Effective DateAug 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateNot specified
    Key ActionSubmit documentation supporting all applicable initial or continuation criteria when requesting prior authorization for Tudriqev.
    SourceLink
    POLICY UPDATE CHANGES

    Disease progression after treatment with an anti-PD-1-containing regimen is now required.

    Coverage criteria were revised to reflect the FDA-approved indication.

    The ICHRA line of business was added.

    18+Minimum age
    8Maximum total doses
    10 mLMaximum volume per dose
    6 monthsApproval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    FDA approvedIndication status